Related Experiment Video

Updated: Jul 16, 2026

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

Potential inhibition of the neuro-neoplastic interactions: the clue of a GPCR-targeted therapy

Jean-Marc Muller1

  • 1Institut de Physiologie et de Biologie Cellulaires, CNRS UMR6187, Pôle Biologie-Santé, Université de Poitiers, Poitiers, France.

Progress in Experimental Tumor Research
|February 23, 2007
PubMed

Insights

Targeting G-protein-coupled receptors (GPCR) offers a novel cancer therapy approach. By targeting GPCRs, particularly neuropeptide receptors, researchers aim to treat cancers involving neuro-neoplastic interactions and perineural invasion.

Area of Science:

  • Oncology
  • Neuroscience
  • Pharmacology

Background:

  • Neurotrophins, neurotransmitters, and guidance molecules influence cancer progression and prognosis.
  • G-protein-coupled receptors (GPCRs) are crucial drug targets, often overexpressed in cancer cells, making them valuable for imaging and targeted radiotherapy.
  • The tumor microenvironment features GPCR ligands that regulate tumor cell proliferation, migration, and survival, mediating neuro-neoplastic interactions.

Purpose of the Study:

  • To review the potential of targeting specific GPCRs, especially neuropeptide receptors, for novel cancer therapies.
  • To explore therapeutic strategies for cancers with neuronal infiltration or perineural invasion.
  • To consider molecular mechanisms involving GPCRs in neuro-neoplastic processes.

Main Methods:

  • Literature review focusing on GPCRs in cancer and neuro-neoplastic interactions.
  • Analysis of GPCR ligands within the tumor microenvironment.
  • Examination of molecular mechanisms linking GPCRs to cancer progression.

Main Results:

  • GPCRs are implicated in regulating tumor cell behavior and mediating interactions between neural and neoplastic cells.
  • Targeting GPCRs, particularly neuropeptide receptors, presents a promising avenue for cancer therapy.
  • Understanding GPCRs' role is key for developing treatments for cancers with neural involvement.

Conclusions:

  • Targeting GPCRs offers a novel therapeutic strategy for various cancers, especially those with neuro-neoplastic interactions or perineural invasion.
  • Further research into GPCRs and their ligands can lead to advanced cancer treatments and imaging techniques.
  • The study highlights the importance of neuro-neoplastic crosstalk in cancer and the therapeutic potential of targeting GPCRs.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...